The tally, one vote per house
24 of 29 research houses agree, +11 houses in 30 days. See which houses, free →
Investors are reportedly moving money out of megacap tech and AI-linked stocks into healthcare, staples, energy and financials, which has lifted equal-weight and value indexes. Of the 29 houses covering the theme, 24 argue for it, 3 against and 2 take a mixed view, with 9 more houses added over the last 30 days. Critics warn that flows are becoming concentrated and indiscriminate, and that a tech-led rebound could still reassert leadership.
Each house counts once: its newest view on the theme in the last 60 days. The counts are computed, not written by AI; the summary is AI-written from the houses’ views, without names.
Who the houses are
- Asset managers13
- Banks9
- Independent research firms4
- Podcasts3
Types only: names are shown to members. See who said what, free →
Houses discussing it, 12 weeks
Houses with a view in the 60 days to each week’s end. Latest: 29 houses on 3 Nov.
What the theme implies
- US equities higher
Positioning
Source: CFTC Commitments of Traders; FinChiefs calculations. Report of 27 Oct 2026. Positioning data →
Named in research
No fund, ETF or index has been named by at least 2 research houses for this theme yet.
Questions
What is the “Tech-to-value rotation” theme?
Money is shifting from megacap tech and AI-linked stocks into healthcare, staples, energy and financials, lifting equal-weight and value indexes. It is one of 70 themes FinChiefs counts across published research from banks, asset managers, independent research firms and podcasts.
How many research houses agree?
24 of 29 research houses agree (83%), counting each house's newest view in the last 60 days: 24 agree, 2 are mixed and 3 disagree. That is +11 houses in 30 days. Members see each house by name.
Which instruments do research houses name for this theme?
No fund, ETF or index has been named by at least 2 research houses for this theme yet.
Is this investment advice?
No. Themes summarise what research houses argue. FinChiefs takes no view of its own. Instruments shown are the ones research houses name, not selected or endorsed by FinChiefs. Not investment advice. No prices are shown and no instrument pays to appear.
The Daily Digest in your inbox
Every morning, what published research argued the day before: the cross-asset and macro read in full, then every market in a line.